5:04 PM
 | 
Aug 24, 2012
 |  BC Extra  |  Company News

Pozen gains on regulatory update

Pozen Inc. (NASDAQ:POZN) gained $0.42 to $6.72 on Friday after providing an update on its regulatory plans for PA32540 and the lower dose formulation, PA8140, following a meeting with FDA. The company now plans to submit a combined NDA for both products in 1H13 for...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >